Angeline Price

Ms. Angeline Price


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EBEilidh Bruce
Eilidh Bruce
FBFenella Barlow-Pay
Fenella Barlow-Pay
RSRoxanna Short
Roxanna Short
AVArturo Vilches-Moraga
Arturo Vilches-Moraga
APAngeline Price
Angeline Price
Phyo MyintPhyo Myint
Phyo Myint
Coronavirus disease 2019 (COVID-19) infection causes acute lung injury, resulting from aggressive inflammation initiated by viral replication. There has been much speculation about the potential role of non-steroidal inflammatory drugs (NSAIDs), which increase the expression of angiotensin-converting enzyme 2 (ACE2), a binding target for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to enter the host cell, which could lead to poorer outcomes in COVID-19 disease. The aim of this study was to examine the association between routine use of NSAIDs and outcomes in hospitalised patients with COVID-19. This was a multicentre, observational study, with data collected from adult patients with COVID-19 admitted to eight UK hospitals. Of 1222 patients eligible to be included, 54 (4.4%) were routinely prescribed NSAIDs prior to admission. Univariate results suggested a modest protective effect from the use of NSAIDs, but in the multivariable analysis, there was no association between prior NSAID use and time to mortality (adjusted HR (aHR) = 0.89, 95% CI 0.52–1.53, p = 0.67) or length of stay (aHR 0.89, 95% CI 0.59–1.35, p = 0.58). This study found no evidence that routine NSAID use was associated with higher COVID-19 mortality in hospitalised patients; therefore, patients should be advised to continue taking these medications until further evidence emerges. Our findings suggest that NSAID use might confer a modest benefit with regard to survival. However, as this finding was underpowered, further research is required.

29 September 2020 in BMJ Open
Verified
Journal Article
Open access
PDF file
APAngeline Price
Angeline Price
FBFenella Barlow-Pay
Fenella Barlow-Pay
SDSiobhan Duffy
Siobhan Duffy
LPLyndsay Pearce
Lyndsay Pearce
AVArturo Vilches-Moraga
Arturo Vilches-Moraga
JHJonathan Hewitt
Jonathan Hewitt
Introduction This protocol describes an observational study which set out to assess whether frailty and/or multimorbidity correlates with short-term and medium-term outcomes in patients diagnosed with COVID-19 in a European, multicentre setting. Methods and analysis Over a 3-month period we aim to recruit a minimum of 500 patients across 10 hospital sites, collecting baseline data including: patient demographics; presence of comorbidities; relevant blood tests on admission; prescription of ACE inhibitors/angiotensin receptor blockers/non-steroidal anti-inflammatory drugs/immunosuppressants; smoking status; Clinical Frailty Score (CFS); length of hospital stay; mortality and readmission. All patients receiving inpatient hospital care >18 years who receive a diagnosis of COVID-19 are eligible for inclusion. Long-term follow-up at 6 and 12 months is planned. This will assess frailty, quality of life and medical complications. Our primary analysis will be short-term and long-term mortality by CFS, adjusted for age (18–64, 65–80 and >80) and gender. We will carry out a secondary analysis of the primary outcome by including additional clinical mediators which are determined statistically important using a likelihood ratio test. All analyses will be presented as crude and adjusted HR and OR with associated 95% CIs and p values. Ethics and dissemination This study has been registered, reviewed and approved by the following: Health Research Authority (20/HRA1898); Ethics Committee of Hospital Policlinico Modena, Italy (369/2020/OSS/AOUMO); Health and Care Research Permissions Service, Wales; and NHS Research Scotland Permissions Co-ordinating Centre, Scotland. All participating units obtained approval from their local Research and Development department consistent with the guidance from their relevant national organisation. Data will be reported as a whole cohort. This project will be submitted for presentation at a national or international surgical and geriatric conference. Manuscript(s) will be prepared following the close of the project.

4 October 2024 in British Journal of Anaesthesia
Verified
Journal Article
Open access
APAngeline Price
Angeline Price
EMElizabeth McLennan
Elizabeth McLennan
SKStephen R Knight
Stephen R Knight
NRNicola Reeves
Nicola Reeves
SCSusan Chandler
Susan Chandler
EGELF2 Study Group
ELF2 Study Group
Older adults (≥65 yr) account for the majority of emergency laparotomies in the UK and are well characterised with reported outcomes. In contrast, there is limited knowledge on those patients that require emergency laparotomy but do not undergo surgery (NoLaps). A multicentre cohort study (n=64 UK surgical centres) recruited 750 consecutive NoLap patients (February 15th - November 15th 2021, inclusive of a 90-day follow up period). Each patient was admitted to hospital with a surgical condition treatable by an emergency laparotomy (defined by The National Emergency Laparotomy Audit (NELA) criteria), but a decision was made not to undergo surgery (NoLap). NoLap patients were predominately female (452 patients, 60%), of advanced age (median age 83.0 yr, interquartile range 77.0-88.8), frail (523 patients, 70%), and had severe comorbidity (750 patients, 100%); 99% underwent CT scanning. The commonest diagnoses were perforation (26%), small bowel obstruction (17%), and ischaemic bowel (13%). The 90-day mortality was 79% and influencing factors were >80 yr, underweight BMI, elevated serum lactate or creatinine concentration. The majority of patients died in hospital (77%), with those with ischaemic bowel dying early. For the 21% of NoLap patients that survived to 90 days, 77% returned home with increased care requirements. This study reports that the NoLap patient population present significant medical challenges because of their extreme levels of comorbidity, frailty, and physiology. Despite these complexities a fifth remained alive at 90 days. Further work is underway to explore this high-risk decision-making process. ISRCTN14556210.

15 May 2026 in British Journal of Anaesthesia
Verified
Journal Article
Open access
APAngeline Price
Angeline Price
SKStephen R. Knight
Stephen R. Knight
EMElizabeth McLennan
Elizabeth McLennan
NRNicola Reeves
Nicola Reeves
SCSusan Chandler
Susan Chandler
SMSusan Moug
Susan Moug
A recent study (ELF2, 2024) showed that older adults (≥65 yr) who require, but do not undergo, emergency laparotomy (the NoLap population) are very old and living with high levels of frailty and multimorbidity. We report on the second aim of this study: to explore the decision-making process behind the decision not to operate. A prospective cohort study recruited 750 consecutive NoLap patients from 64 UK emergency surgical units (February-November 2021). Each NoLap patient had a surgical condition treatable by an emergency laparotomy as defined by the National Emergency Laparotomy Audit criteria. Shared decision-making (patient and family or both member involvement) and multispeciality decision-making (two or more specialities) factors were explored. Free text answers underwent qualitative analysis. There were 12.4% of patients with an advanced directive in NoLap cases. Patient involvement in the decision was documented in 65.9% of NoLap cases (34.4% assisted by a family member). For those not involved (33.2%), 67.5% had a family member consulted. In ≥9.0% of NoLap cases, neither the patient nor a family member was involved. Multispeciality decision-making occurred in 66.2% of cases, with the surgical team involved in almost all (99.9%-84.8% at consultant level and 73.5% in person). Medical teams were the next highest speciality to be involved (33.0%), with geriatricians present in only 8.7%. Consultant input declined over weekends and overnight. Qualitative content analysis identified a broad range of patient and clinical factors warranting further exploration. Multispeciality, shared decision-making regarding emergency laparotomy is possible in a time-pressured emergency surgical setting.

27 May 2025 in Anaesthesia
Verified
Journal Article
Closed access
APAngeline Price
Angeline Price
LPLyndsay Pearce
Lyndsay Pearce
JGJane Griffiths
Jane Griffiths
JSJonathan Smith
Jonathan Smith
LTLouise Tomkow
Louise Tomkow
FTfor the National Emergency Laparotomy Audit team
for the National Emergency Laparotomy Audit team

3 May 2021
Verified
Conference Paper
Open access
MCM.J. Cummings
M.J. Cummings
BBB. Bakamutumaho
B. Bakamutumaho
APAngeline Price
Angeline Price
NON. Owor
N. Owor
JKJohn Timothy Kayiwa
John Timothy Kayiwa
MOM.R. O'DOnnell
M.R. O'DOnnell